Background: There are limited data on the pharmacogenetics and pharmacokinetics of the CNS penetration of efavirenz.
Introduction
The fixed-dose combination of efavirenz, tenofovir and emtricitabine has been recommended as first-line ART for HIV-infected adults. 1 However, prolonged ART exposure may impact cognitive function if ART neurotoxicity exceeds CNS viral suppression efficacy-a hypothesis supported by preclinical and clinical data. 2 Efavirenz in particular has demonstrated neurotoxicity in in vitro studies. 3 Interrupting ART after a median of 4.5 years was associated with improved cognitive function, especially among efavirenz recipients. 4 In a randomized controlled trial (RCT), patients starting efavirenz, tenofovir and emtricitabine rather than PIs or all-NRTI regimens had less neurocognitive improvement after 48 weeks. Human genetic variants have been associated with antiretroviral pharmacokinetics and pharmacodynamics, but ART CNS-targeted strategies have not considered pharmacogenetics. 6 Efavirenz is primarily metabolized by cytochrome P450 (CYP) 2B6 into 8-hydroxyefavirenz while CYP2A6 generates the 7-hydroxy-efavirenz metabolite. 7 CYP2B6 516G!T (rs3745274) predicts increased plasma efavirenz exposure. [8] [9] [10] [11] [12] [13] The CYP2B6 516TT genotype is more common in Africans and African Americans than in Caucasians. 8, 14, 15 Additional polymorphisms that are less frequent than 516G!T in Africans and African Americans, 983T!C (rs28399499) and CYP2B6 15582C!T (rs4803419), also predict increased plasma efavirenz exposure. 7, 15 The CYP2B6 983C allele is found almost exclusively with African ancestry. 15, 16 Polymorphisms in genes beyond CYP2B6 have been infrequently reported to be associated with efavirenz concentrations including polymorphisms in CYP2A6. 12, 17 Polymorphisms in CYP2B6 that predict higher efavirenz plasma concentrations predispose to efavirenz-mediated neurotoxicity. 8, 18 Patients with CYP2B6 slow-metabolizer genotypes also have higher CSF efavirenz exposure. 19 In vitro studies have implicated efavirenz and especially its metabolite 8-hydroxy-efavirenz in neuronal toxicity. 3, 20, 21 In a CSF substudy of the ENCORE1 trial, 8-hydroxy-efavirenz exposure correlated with adverse neuropsychiatric outcomes. 19 However, CYP2B6 516G!T only predicted efavirenz plasma and CSF concentrations and not 8-hydroxy-efavirenz plasma or CSF concentrations. 19, 22, 23 Blood-brain barrier (BBB) and blood-CSF barrier (BCSFB) transporters affect influx and efflux of drugs including antiretrovirals. 24 , 25 The superfamily of solute carrier (SLC) genes, including SLCO2B1, SLCO1A2 and SLCO1B1, influence influx transporter expression in the BBB and BCSFB. 26, 27 Efflux transporters in the BBB and BCSFB are influenced by ATP-binding cassette (ABC) genes including ABCB1 [which encodes P-glycoprotein (P-gp)], ABCG2, ABCC4 and ABCC5. 27, 28 There are conflicting data regarding whether efavirenz is a P-gp substrate and whether ABCB1 polymorphisms predict efavirenz concentrations. 10, 29, 30 ABCC4 polymorphisms (rs1751034 and rs2274407) have been associated with lower and higher maximum plasma efavirenz concentrations, respectively, and ABCG2 rs2231142 has been associated with an increased risk of abnormal dreams with efavirenz. 31, 32 Africans are the most genetically diverse population worldwide. 33 South Africa has the world's largest ART programme, with most patients currently receiving efavirenz/tenofovir/emtricitabine. 34 Genetic polymorphisms that affect metabolizing enzymes or transporters may therefore affect efavirenz CSF penetration. We investigated associations between genetic polymorphisms and CSF exposure of efavirenz and 8-hydroxy-efavirenz in black South Africans. We also explored pharmacokinetic-pharmacodynamic relationships of CSF efavirenz and 8-hydroxy-efavirenz with neurocognitive performance.
Patients and methods

Participants
Adults (aged 18 and 70 years) who participated in an RCT (PACTR201310000635418) investigating lithium for HIV-associated neurocognitive impairment [global deficit score (GDS) of 0.5] were invited to participate in this study. 35 We also invited participants who were screened for the RCT but were excluded based on cognitive impairment criteria. We included participants established on efavirenz-based ART for at least 6 months with suppressed plasma HIV-1 RNA. All participants provided written informed consent. The study was approved by the University of Cape Town Human Research Ethics Committee (HREC 071/2013).
Pharmacokinetic sampling
We collected paired plasma and CSF samples for assays of efavirenz and its metabolites. Participants recorded dosing time the night before and were admitted in the morning for pharmacokinetic sampling. Mid-dosing lumbar punctures were performed. Whole blood was collected within 45 min of CSF sampling, centrifuged within 1 h of collection, aliquoted and stored at #80 C until analysis. CSF was aliquoted and stored at #80 C until analysis.
Measurement of efavirenz and its metabolites
Drug assays were performed at two laboratories. The analytical laboratory in the Division of Clinical Pharmacology at the University of Cape Town quantified total efavirenz in plasma and CSF using validated LC/MS-MS assays. The lower limit of quantification (LLOQ) for plasma and CSF efavirenz was 19.5 and 0.5 ng/mL, respectively. The Bioanalytical Facility, Department of Molecular and Clinical Pharmacology at the University of Liverpool quantified total CSF 8-hydroxy-efavirenz, plasma 8-hydroxy-efavirenz and plasma 7-hydroxy-efavirenz using validated LC/MS-MS assays. 22 We could not quantify CSF 7-hydroxy-efavirenz. The LLOQ for CSF 8-hydroxy-efavirenz, plasma 8-hydroxy-efavirenz and plasma 7-hydroxyefavirenz was 3.125 ng/mL, 5.0 ng/mL and 5.0 ng/mL, respectively. Concentrations below the limit of quantification were analysed as missing data.
Characterization of genetic polymorphisms
We extracted DNA from buffy coats using QIAsymphony V R . Genotyping was done using Illumina MEGA EX (Illumina, San Diego, CA, USA). SNPs that were not genotyped were imputed. SNPs were extracted for seven genes +50 kb in each direction: ABCB1 (301 SNPs), ABCC4 (630 SNPs), ABCC5 (225 SNPs), ABCG2 (164 SNPs), CYP2A6/B6 (202 SNPs), SLCO1A2 (406 SNPs) and SLCO2B1 (118 SNPs). SNPs were excluded for genotyping efficiency less than 99%, a 5% minor allele frequency cut-off, and Hardy-Weinberg equilibrium (HWE) P values ,0.00001. We further performed targeted genotyping of CYP2B6 516G!T (rs3745274) and CYP2A6 #48A!C (rs28399433) by TaqMan TM (Applied Biosystems, Foster City, CA, USA) and of CYP2B6 983T!C (rs28399499), CYP2B6 15582C!T (rs4803419), SLCO1B1 521T!C (rs4149056) and SLCO1B1 (rs4149032) by MassARRAY V R iPLEX Gold (Sequenom Inc., San Diego, CA, USA). All samples were genotyped in duplicate. The final data set included 2049 SNPs from 47 participants. All genotyping was done at Vanderbilt Technologies for Advanced Genomics (VANTAGE). Laboratory personnel with no knowledge of clinical data performed the genotyping. Metabolizer genotype groups for CYP2B6 were assigned as follows: extensive metabolizer (CYP2B6 15882CC-516GG-
Furthermore, among participants with a slow-metabolizer genotype, additional assessment of CYP2A6 #48A!C (rs28399433) was assessed to categorize the metabolizer status into an ordinal 12-level metabolizer status as described elsewhere. 7, 36 Neurocognitive performance
We assessed neurocognitive impairment to provide a GDS. 37 We previously reported the domains and tests included. 35 We screened for symptoms of depression using the Center for Epidemiologic Studies Depression (CES-D) scale. 38 Decloedt et al.
Efavirenz and metabolite neurotoxicity
We compared CSF efavirenz and 8-hydroxy-efavirenz concentrations with concentrations reported to be associated with neuronal damage in vitro (31.6 ng/mL and 3.3 ng/mL, respectively). 20 
Viral load assessment
We determined HIV-1 RNA concentrations in plasma and CSF using the Abbott RealTime HIV-1 assay (Abbott Park, IL, USA.). We considered participants to be virologically suppressed if the viral load was ,400 copies/mL. In plasma and CSF, the lower limit of detection was 40 copies/mL. In CSF, we performed a previously described nested PCR and automated DNA sequencing method to detect HIV-1 transactivator viral protein (Tat) mutations, which have been associated with HIV-1-associated neurocognitive impairment. 39, 40 
BBB integrity
We calculated the CSF:blood albumin ratio [CSF albumin (mg/L):serum albumin (g/L)] to determine BBB integrity. The BBB was considered intact if this ratio was less than 6.8 in participants ,45 years of age, and less than 10.2 in participants 45 years of age. 41 
Pharmacokinetic statistical analysis
Pharmacokinetic data were not normally distributed and were expressed as medians (IQR) and geometric means (95% CI). We corrected for plasma protein binding and estimated protein-free plasma concentrations by multiplying total plasma concentrations by the protein-free concentrations reported in the literature (efavirenz 0.22%). 42 Total CSF concentrations were considered to be similar to CSF protein-free concentrations. 42 Pearson's r correlation was used to assess correlations between plasma and CSF concentrations. We performed statistical analysis using STATA version 15.0 (StataCorp, College Station, TX, USA). Graphs were created using GraphPad Prism version 7.03 for Windows (GraphPad Software, La Jolla, CA, USA).
Genetic associations
Genetic associations with pharmacokinetic parameters were analysed by multivariate linear or logistic regression. Pharmacokinetic data were logtransformed (log 10 ) for genetic analysis. We used ratios of measured concentrations (total in CSF and plasma) without correcting for protein binding. CSF:plasma ratios were calculated using raw concentrations then log 10 -transformed. For efavirenz analyses we subsequently adjusted for CYP2B6 516G!T, 983T!C and 15582C!T. We performed genetic association analyses in PLINK version 1.9 (http://zzz.bwh.harvard.edu/plink/). For the primary analyses, we employed linkage disequilibrium (LD) pruning with an LD r 2 threshold of 0.95 within a 50 kb window at 5 kb increments. The final analysis dataset included 880 SNPs that met the LD-pruning threshold. We used Bonferroni correction to adjust for multiple testing (P " 0.05 divided by 880 SNPs). We generated an LD plot using Haploview (https://www.broadin stitute.org/haploview/haploview).
Results
Study participant characteristics
We sampled 47 participants (Table 1) , 33 (70%) of whom had mild to moderate neurocognitive impairment. All participants self-identified as black Xhosa and all were virologically suppressed in plasma. Four participants had detectable viral loads, the highest being 128 copies/mL. CSF viral loads were ,40 copies/mL in all participants. Five participants had detectable HIV-1 Tat DNA, all of whom had the C30C31S substitution. We were able to determine the CSF:blood albumin ratio in 31 (66%) of 47 participants, with a median value of 2.6 (range 1.1 to 5.2), indicating an intact BBB.
Efavirenz pharmacokinetics
Concentrations of efavirenz (plasma and CSF), 8-hydroxy-efavirenz (plasma and CSF) and 7-hydroxy-efavirenz (plasma) are described in Table 2 . Plasma 8-hydroxy-efavirenz and 7-hydroxy-efavirenz concentrations correlated with plasma efavirenz concentrations (P , 0.0001 for each) (Figure 1a and b) . CSF and plasma efavirenz concentrations were correlated (P , 0.0001) (Figure 1c ). There was no correlation between CSF 8-hydroxy-efavirenz and plasma efavirenz, CSF 8-hydroxy-efavirenz and plasma 8-hydroxy-efavirenz or plasma 7-hydroxy-efavirenz and plasma 8-hydroxy-efavirenz (Figure 1d-f) . There was no statistically significant association of CSF:plasma ratios versus time after dosing (Figure 2 ). CSF efavirenz concentrations were above the IC 50 (1.3 ng/mL) in all participants. 42 CNS PK and genomics of EFV
JAC
Genetic associations for efavirenz
Genotyping of four polymorphisms with known effects on efavirenz (CYP2B6 516G!T, 983T!C, 15582C!T and CYP2A6 #48A!C) and two polymorphisms in SLCO1B1 (rs4149056 and rs4149032) was successful in all 47 participants. SLCO1B1 rs4149056 was monomorphic. In 43 (91%) of 47 participants, an additional 2043 polymorphisms from ABCB1, ABCC4, ABCC5, ABCG2, CYP2A6, CYP2B6, SLCO1A2 and SLCO2B1 were successfully genotyped. All 2048 polymorphisms were in HWE based on a Bonferroni-adjusted P value threshold of 0.00002; 18 had unadjusted P values ,0.05 (data not shown). The 880 polymorphisms included in the final dataset based on LD pruning were in HWE based on a Bonferroniadjusted P value threshold of 5.7%10
#05
. Ten polymorphisms had unadjusted P values ,0.05. Decloedt et al.
Plasma efavirenz concentrations
Relationships between CYP2B6 slow-metabolizer genotypes and efavirenz concentrations are described in Table 3 . Plasma efavirenz concentrations were significantly higher in CYP2B6 slow metabolizers compared with intermediate and extensive metabolizers ( Figure S1 , available as Supplementary data at JAC Online). In multivariable linear regression analysis adjusted for CYP2B6 516G!T, the polymorphism associated at P , 0.05 was CYP2B6 983T!C (b " 0.38, 95% CI " 0.14 to 0.61, P " 2.7%10
#03
). See Table S1 .
Plasma 8-hydroxy-efavirenz concentrations
No polymorphisms were significant after correcting for multiple testing in multivariate analyses adjusting for CYP2B6 516G!T, or CYP2B6 516G!T and 983T!C (Table S1 ).
Plasma 7-hydroxy-efavirenz concentrations
Plasma 7-hydroxy-efavirenz concentrations were significantly higher in CYP2B6 slow metabolizers compared with intermediate and extensive metabolizers (Table 3) . After adjusting for CYP2B6 516G!T, CYP2B6 983T!C remained significant (b " 0.59, 95% CI " 0.22 to 0.96, P " 3.7%10
#03
) and ABCB1 rs11578656 became significant (b " #0.71, 95% CI " #1.01 to #0.42, P " 2.9%10
#05
). See Table S1 . The association between ABCB1 rs11578656 and log 10 -transformed plasma 7-hydroxy-efavirenz concentrations remained significant after correcting for multiple testing in multivariate analyses adjusting for CYP2B6 516G!T and CYP2B6 983T!C (b " #0.65, 95% CI " #0.92 to #0.37, P " 4.1%10
). Two additional CYP2A6 polymorphisms became significant in multivariate analyses adjusting for CYP2B6 516G!T and CYP2B6 983T!C: CYP2A6 rs10853742 (b " #0.55, 95% CI " #0.78 to #0.32, P " 3.5%10
) and the known polymorphism CYP2A6 #48A!C (b " #0.59, 95% CI " #1.01 to #0.16, P " 0.01).
CSF efavirenz concentrations
CSF efavirenz concentrations were significantly higher in CYP2B6 slow metabolizers compared with intermediate and extensive metabolizers (Table 3) . After adjusting for CYP2B6 516G!T, the association between CYP2B6 983T!C and log 10 -transformed CSF efavirenz concentrations persisted (b " 0.36, 95% CI " 0.10 to 0.62, P " 1.0%10
#02
). See Table S2 . Tables 4, 5 and Table S2 , respectively. No polymorphisms were significant in multivariate analyses.
CSF:plasma efavirenz concentration ratio, CSF:plasma 8-hydroxy-efavirenz concentration ratio and CSF 8-hydroxy-efavirenz concentrations
Plasma 8-hydroxy-efavirenz:efavirenz ratios
After adjusting for CYP2B6 516G!T, the association between CYP2B6 983T!C and log 10 -transformed 8-hydroxy-efavirenz:efavirenz ratios remained significant (b " #0.31, 95% CI " #0.45 to #0.16, P " 1.8%10
#04
). See Table S3 .
Plasma 7-hydroxy-efavirenz:efavirenz ratios
In multivariate linear regression models, a previously described CYP2B6 polymorphism (rs2279345) was significantly associated with lower 7-hydroxy-efavirenz:efavirenz ratios (b " #0.28, 95% CI " #0.43 to #0.12, P " 1.2%10
#03
) at P , 0.05 (Table S3 ). The association remained significant at P , 0.05 after adjusting for CYP2B6 516G!T, CYP2B6 516G!T and CYP2B6 983T!C.
CSF 8-hydroxy-efavirenz:efavirenz ratios
Linear regression analysis results for genetic associations with log 10 -transformed CSF 8-hydroxy-efavirenz:efavirenz ratios were available in 17 participants (Table S3) . After adjusting for CYP2B6 516G!T and CYP2B6 983T!C, the association between CYP2A6 #48A!C and higher log 10 -transformed CSF 8-hydroxy-efavirenz:efavirenz ratios became significant (b " 0.54, 95% CI " 0.05 to 1.03, P " 4.8%10
#02
).
LD
To demonstrate independent associations, the LD plots are displayed in Figures S2 to S8 .
Pharmacokinetic-pharmacodynamic associations with neurocognitive performance
We found no significant correlation between GDS and CSF concentrations of efavirenz or 8-hydroxy-efavirenz. Detectable CSF 8-hydroxy-efavirenz tended to be associated with impaired executive function on the Colour Trails Test (P " 0.043). Participants with detectable CSF 8-hydroxy-efavirenz had a higher GDS compared with participants without detectable CSF 8-hydroxy-efavirenz (1.0 compared with 0.82), but this was not statistically significant. The GDS in the five participants in whom HIV-1 Tat DNA was detected were similar to those in whom Tat DNA was not detected.
Discussion
We investigated whether genetic polymorphisms are associated with CSF disposition of efavirenz in black South African adults. In multivariate analysis CYP2B6 983T!C predicted plasma efavirenz, plasma 7-hydroxy-efavirenz, plasma 8-hydroxy-efavirenz:efavirenz ratio and CSF efavirenz. Lower plasma 7-hydroxy-efavirenz concentrations were independently associated with CYP2A6 rs10853742, ABCB1 rs115780656 and CYP2A6 #48A!C. The CYP2A6 #48A!C polymorphism was also independently associated with higher CSF 8-hydroxy-efavirenz:efavirenz ratio. The CYP2B6 rs2279345 Decloedt et al. Table 4 . CNS PK and genomics of EFV JAC Table 5 . Decloedt et al.
polymorphism was associated with lower plasma 7-hydroxy-efavirenz: efavirenz ratio in multivariate analyses adjusting for CYP2B6 516G!T and 983T!C (P , 0.05). No polymorphisms were associated with CSF:plasma ratios of efavirenz, plasma or CSF concentrations of 8-hydroxy-efavirenz or neurocognitive performance. We expected CSF 8-hydroxy-efavirenz concentrations to be higher in extensive metabolizers as it is formed via the CYP2B6 enzymatic pathway. However, similar to the findings of others, 8-hydroxy-efavirenz concentrations in plasma and CSF remained constant irrespective of metabolizer status. 19, 22, 23 It is possible that the small number of participants (17 of 47) with detectable CSF 8-hydroxy-efavirenz concentrations contributed to the lack of association between the metabolizer status and CSF 8-hydroxyefavirenz concentrations. Winston et al. 19 proposed that CSF 8-hydroxy-efavirenz concentrations are independent of metabolizer status as it is 8-hydroxy-efavirenz spillover from the plasma, or that efavirenz is metabolized to 8-hydroxy-efavirenz in the CNS, trapping 8-hydroxy-efavirenz within the CNS compartment. We found that CYP2A6 #48A!C was independently associated with a higher CSF 8-hydroxy-efavirenz:efavirenz ratio, which may suggest that in CYP2B6 slow metabolizers, efavirenz may be metabolized to 8-hydroxy-efavirenz in the CNS by the accessory pathway CYP2A6. However, we did not find a statistically significant association with CYP2A6 #48A!C and CSF 8-hydroxy-efavirenz or plasma 8-hydroxy-efavirenz.
We explored pharmacokinetic-pharmacodynamic relationships of efavirenz and neurocognition. Although CSF efavirenz and 8-hydroxy-efavirenz concentrations were above the in vitro CSF toxicity threshold, in 15.2% and 29.8% of participants, respectively, we did not find a relationship between GDS performance and plasma or CSF efavirenz concentrations or CSF 8-hydroxy-efavirenz concentrations. Participants with detectable CSF 8-hydroxy-efavirenz scored worse on the Colour Trails Test (P " 0.04) and had a higher GDS (median 1.39 compared with median 1.0), which was not statistically significant. It is possible that CYP2A6 #48A!C predisposes CYP2B6 slow metabolizers to higher CSF 8-hydroxy-efavirenz concentrations and worse neurocognitive performance. Various cellular mechanisms for efavirenz toxicity have been proposed. 46 Higher efavirenz concentrations, which are associated with CYP2B6 slow-metabolizer status, are associated with neurological symptoms, which may include serious presentations such as encephalopathy. 18, 47 In a CSF substudy of the ENCORE1 trial, 8-hydroxy-efavirenz exposure correlated with adverse neuropsychology outcomes. 19 Our study has limitations. We had limited power, with 47 participants, to detect genetic associations between infrequent genotypes with small effect sizes (increase in plasma or CSF concentrations). The CYP2A6 #48A!C polymorphism has been associated with increased plasma efavirenz concentrations in CYP2B6 slow metabolizers, but we found no association as only three participants with CYP2B6 slow-metabolizer genotype carried a single CYP2A6 #48A!C allele. 36 This may have also limited our ability to detect associations between CYP2B6 15582C!T and plasma efavirenz concentrations, as 15582CT heterozygosity has been associated with increased plasma efavirenz exposure, and there were no 15582TT homozygotes in our study. 7 We were not able to detect pharmacokinetic-pharmacodynamic associations due to limited power to detect smaller differences in cognitive impairment. However, to our knowledge this is the largest sample size examining pharmacogenetic, pharmacokinetic and pharmacodynamic associations with CSF efavirenz. Our study was cross-sectional. Neurocognitive changes would have been better assessed longitudinally. We did not measure unbound concentrations of efavirenz, and protein-free CSF:plasma concentrations of efavirenz in particular may have more accurately reflected the pharmacodynamically active concentrations.
In summary, we identified novel genetic associations with plasma efavirenz, plasma 7-hydroxy-efavirenz, plasma 7-hydroxyefavirenz:efavirenz ratio, plasma 8-hydroxy-efavirenz:efavirenz ratio, CSF efavirenz and CSF 8-hydroxy-efavirenz:efavirenz ratio. No polymorphisms were associated with: CSF:plasma ratios of efavirenz; plasma or CSF 8-hydroxy-efavirenz concentrations; or neurocognitive performance.
